Suppr超能文献

现代队列中多发性硬化症患者从诊断到15年的治疗结局

Outcomes in a Modern Cohort of Treated Patients with Multiple Sclerosis from Diagnosis Up to 15 Years.

作者信息

Scott Thomas F, Desai Troy, Hackett Chris, Gettings Edward J, Hentosz Teresa, Elmalik Wisam, Schramke Carol J

出版信息

Int J MS Care. 2020 May-Jun;22(3):110-114. doi: 10.7224/1537-2073.2019-005. Epub 2019 Dec 5.

Abstract

BACKGROUND

Before disease-modifying therapies (DMTs) were available, the natural history of multiple sclerosis (MS) regarding attainment of accepted disability milestones was reported with fairly wide variance comparing outcomes across studies. The influence of DMTs on these outcomes is unknown. This study aimed to calculate attainment of disability milestones during the first 15 years after onset of DMT-treated relapsing forms of MS (RMS).

METHODS

As a retrospective study, all available disability data (collected routinely) on all newly diagnosed patients with RMS seen and initially diagnosed in a single clinic between 1989 and 2006 were reviewed. Times from first symptoms and diagnosis until first treatment with DMTs were also reviewed. Time-to-event statistics were applied using disability milestones.

RESULTS

Mean follow-up of 184 adult patients from symptom onset was 13.7 years. Of patients followed up for 15 years after onset, 16 of 86 (19%) reached an Expanded Disability Status Scale (EDSS) score of 6.0. Estimated median time to reach an EDSS score of 3.0 was 10.7 years and to reach an EDSS score of 4.0 was 18.1 years.

CONCLUSIONS

There were striking differences between the present results and older data sets and similar results to the few available modern data sets. This analysis of a modern treated RMS cohort provides outcomes data that may be compared favorably with the natural history of RMS.

摘要

背景

在疾病修饰疗法(DMTs)出现之前,关于多发性硬化症(MS)达到公认残疾里程碑的自然史,不同研究报告的结果差异较大。DMTs对这些结果的影响尚不清楚。本研究旨在计算DMT治疗复发型MS(RMS)发病后前15年中达到残疾里程碑的情况。

方法

作为一项回顾性研究,我们回顾了1989年至2006年间在单一诊所初诊的所有新诊断RMS患者的所有可用残疾数据(常规收集)。还回顾了从首次出现症状和诊断到首次使用DMT治疗的时间。使用残疾里程碑应用事件发生时间统计。

结果

184例成年患者从症状发作开始的平均随访时间为13.7年。在发病后随访15年的患者中,86例中有16例(19%)的扩展残疾状态量表(EDSS)评分达到6.0。达到EDSS评分3.0的估计中位时间为10.7年,达到EDSS评分4.0的估计中位时间为18.1年。

结论

目前的结果与较旧的数据集存在显著差异,与少数可用的现代数据集结果相似。对现代接受治疗的RMS队列的这项分析提供了可与RMS自然史进行良好比较的结果数据。

相似文献

1
Outcomes in a Modern Cohort of Treated Patients with Multiple Sclerosis from Diagnosis Up to 15 Years.
Int J MS Care. 2020 May-Jun;22(3):110-114. doi: 10.7224/1537-2073.2019-005. Epub 2019 Dec 5.
5
Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
Neurol Ther. 2021 Jun;10(1):183-196. doi: 10.1007/s40120-020-00224-1. Epub 2020 Nov 26.
6
Relapsing multiple sclerosis patients treated with disease modifying therapy exhibit highly variable disease progression: a predictive model.
Clin Neurol Neurosurg. 2014 Dec;127:86-92. doi: 10.1016/j.clineuro.2014.09.008. Epub 2014 Oct 2.
7
Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
Mult Scler Relat Disord. 2020 May;40:101956. doi: 10.1016/j.msard.2020.101956. Epub 2020 Jan 17.
8
Is Initial Misdiagnosis Associated with Reaching Disability Milestones in Patients with Multiple Sclerosis?
Medicina (Kaunas). 2020 Apr 10;56(4):170. doi: 10.3390/medicina56040170.
9
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.
Lancet Neurol. 2020 Apr;19(4):307-316. doi: 10.1016/S1474-4422(20)30067-3. Epub 2020 Mar 18.
10
Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
Mult Scler Relat Disord. 2019 Oct;35:119-127. doi: 10.1016/j.msard.2019.07.021. Epub 2019 Jul 25.

本文引用的文献

1
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis.
J Neurol Neurosurg Psychiatry. 2017 Mar;88(3):196-203. doi: 10.1136/jnnp-2016-313976. Epub 2016 Sep 28.
2
The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.
Neurology. 2016 Sep 6;87(10):978-87. doi: 10.1212/WNL.0000000000003078. Epub 2016 Aug 10.
3
Long-term evolution of multiple sclerosis disability in the treatment era.
Ann Neurol. 2016 Oct;80(4):499-510. doi: 10.1002/ana.24747. Epub 2016 Aug 13.
4
Trajectory of MS disease course for men and women over three eras.
Mult Scler. 2017 Apr;23(4):534-545. doi: 10.1177/1352458516655478. Epub 2016 Jul 11.
5
Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
Neurology. 2016 Mar 8;86(10):920-30. doi: 10.1212/WNL.0000000000002441. Epub 2016 Feb 10.
6
Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis.
Neurology. 2015 Aug 25;85(8):722-9. doi: 10.1212/WNL.0000000000001856. Epub 2015 Jul 24.
7
Defining high, medium and low impact prognostic factors for developing multiple sclerosis.
Brain. 2015 Jul;138(Pt 7):1863-74. doi: 10.1093/brain/awv105. Epub 2015 Apr 21.
8
Relapsing multiple sclerosis patients treated with disease modifying therapy exhibit highly variable disease progression: a predictive model.
Clin Neurol Neurosurg. 2014 Dec;127:86-92. doi: 10.1016/j.clineuro.2014.09.008. Epub 2014 Oct 2.
9
Characterising aggressive multiple sclerosis.
J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1192-8. doi: 10.1136/jnnp-2013-304951. Epub 2013 Jun 6.
10
Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.
Neurology. 2012 Apr 24;78(17):1315-22. doi: 10.1212/WNL.0b013e3182535cf6. Epub 2012 Apr 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验